Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA | Zendy

Margarida Augusto | Zendy; Mallik Greene | Zendy; Maëlys Touya | Zendy; Samantha Min Sweeney | Zendy; Heidi C. Waters | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

Author(s) -

Margarida Augusto,

Mallik Greene,

Maëlys Touya,

Samantha Min Sweeney,

Heidi C. Waters

Publication year - 2018

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2018-0010

Subject(s) - medicine , paliperidone palmitate , asenapine , aripiprazole , risperidone , bipolar i disorder , quality of life (healthcare) , quality adjusted life year , bipolar disorder , cost effectiveness , mood , schizophrenia (object oriented programming) , psychiatry , mania , risk analysis (engineering) , nursing

To evaluate the cost-effectiveness of aripiprazole once-monthly 400/300 mg (AOM 400) in maintenance monotherapy treatment of bipolar I disorder (BP-I).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research